American Heart Association comment: FDA announces safety changes on labeling for some statins
2012-03-01
(Press-News.org) The United States Food and Drug Administration (FDA) announced it is revising safety information on the labels of some statins (cholesterol lowering drugs).
Statins are a class of drugs that work in the liver to prevent the formation of cholesterol. They are most effective at lowering the LDL (bad) cholesterol, but also have modest effects on lowering triglycerides (blood fats) and raising HDL (good) cholesterol. High cholesterol is a risk factor for cardiovascular disease and stroke.
The FDA changes to the statin labels include:
Revising the drug labels to remove the need for routine periodic monitoring of liver enzymes in patients taking statins.
Including labeling information about some patients experiencing memory loss and confusion.
Warning healthcare professionals and patients of the potential risk of increased blood sugar levels and of being diagnosed with type 2 diabetes mellitus.
The announcement also alerts health care professionals to new recommendations in the lovastatin label, including drug interactions like those with drugs used to treat HIV (protease inhibitors).
"The FDA's announcement on the label changes does not question the benefit of statins to lowering cholesterol, but it does provide patients and healthcare providers the most current information about the safe use of statins," said Gordon F. Tomaselli, M.D., president of the American Heart Association.
"Not surprising, but important for practitioners with regard to routine liver function test screening, which is no longer recommended, but should be done at baseline and for symptoms. This will change practice although I will remain vigilant in people with prior history of liver disease, people who drink or who are taking multiple drugs metabolized by the liver. Also, the contraindications of use of in particular anti-HIV drugs with Mevacor (lovastatin) are important to reemphasize as is the known but infrequent increase in blood sugar in patients taking statins."
Tomaselli says "while we recommend healthy people focus on prevention using lifestyle changes rather than drug therapy whenever possible, for some people, lifestyle changes aren't enough. As with all therapies, the decision to use statins for primary or secondary prevention must include careful consideration of the risks and benefits, side-effects and cost. Working with your healthcare provider to be sure you're doing what you need to do to stay healthy is the best approach."
INFORMATION:
For more information on lowering your risk factors for heart disease and stroke, visit www.heart.org .
Additional resources:
FDA news release - http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm
Cholesterol lowering drugs information - http://www.heart.org/HEARTORG/Conditions/Cholesterol/PreventionTreatmentofHighCholesterol/Drug-Therapy-for-Cholesterol_UCM_305632_Article.jsp
ADV12-1002
The American Heart Association/American Stroke Association receives funding mostly from individuals. Foundations and corporations donate as well, and fund specific programs and events. Strict policies are enforced to prevent these relationships from influencing the association's science content. Financial information for the American Heart Association, including a list of contributions from pharmaceutical companies and device manufacturers, is available at www.heart.org/corporatefunding .
END
ELSE PRESS RELEASES FROM THIS DATE:
2012-03-01
It had long been assumed that the human sperm cell's mission in life ended once it had transferred its freight of parental DNA to the egg. More recently however, other components of sperm have been implicated in fertilization, and perhaps even in subsequent embryonic development.
In a new study appearing in the Proceedings of the Royal Society, Timothy Karr, a researcher at Arizona State University's Biodesign Institute, along with colleagues from the Universities of Cambridge and Bath, England, examine messenger RNA (mRNA) transcripts present in the sperm of both fruitflies ...
2012-03-01
The prevailing model for planetary accretion, also called fractal assembly, and dating back as far as the 18th century, assumes that the Solar System's planets grew as small grains colliding chaotically, coalescing into bigger ones, colliding yet more until they formed planetesimals. The planetesimals then collided until they formed planets as varied as the Earth and Jupiter.
The model assumes that this occurred in an extremely hot (as high as 1,600 degrees Celsius) environment for the inner Solar System, fostered by a dusty, two-dimensional disk post-dating the Sun.
The ...
2012-03-01
People with schizophrenia who completed 80 hours of intensive, computerized cognitive training exercises were better able to perform complex tasks that required them to distinguish their internal thoughts from reality.
As described in the journal Neuron (2/22/12), a small clinical study conducted at the San Francisco VA Medical Center (SFVAMC) and the University of California, San Francisco (UCSF), tested the digital exercises as a new therapy for schizophrenia.
"We predicted that in order to improve complex cognitive functions in neuropsychiatric illness, we must ...
2012-03-01
MadCap Software, Inc. (http://www.madcapsoftware.com), the leader in multi-channel content authoring and a showcase company for Microsoft (NASDAQ: MSFT) Visual Studio and Microsoft XPS, today announced that the newest release of MadPak is now available.
MadPak (http://www.madcapsoftware.com/products/madpak/overview.aspx) is the industry's most comprehensive authoring suite, featuring integrated, XML-based products for complete end-to-end technical communication. The latest release of the suite offers four new product versions: MadCap Flare 8.0 for single-source, multi-channel ...
2012-03-01
EUGENE, Ore. -- (Feb. 29, 2012) -- A rare and endangered monkey in an African equatorial rainforest is providing a look into our climatic future through its DNA. Its genes show that wild drills (Mandrillus leucophaeus), already an overhunted species, may see a dramatic population decline if the forest dries out and vegetation becomes sparser amid warming temperatures, researchers report.
Looking for clues amid 2,076 base pairs of mitochondrial DNA -- genes passed down along female lineages -- researchers discovered genetic signs that coincide with the conditions that ...
2012-03-01
Patients who had leaky mitral heart valves repaired along with bypass surgery had with healthier hearts than those who had bypass only, according to new research presented in the American Heart Association's Emerging Science Series webinar.
The mitral valve separates the heart's left atrium (upper chamber) from the left ventricle (lower chamber). It has two flaps, or cusps, and if the flaps don't close properly, the valve will leak.
"Many patients who need bypass surgery have mild to moderately leaky mitral valves because coronary artery disease causes the heart to enlarge ...
2012-03-01
ROCHESTER, Minn. -- Mitochondria -- subunits inside cells that produce energy -- have long been thought to play a role in Alzheimer's disease. Now Mayo Clinic researchers using genetic mouse models have discovered that mitochondria in the brain are dysfunctional early in the disease. The findings appear in the journal PLoS ONE.
The group looked at mitochondria in three mouse models, each using a different gene shown to cause familial, or early-onset, Alzheimer's disease. The specific mitochondria changes corresponded with the mutation type and included altered mitochondrial ...
2012-03-01
MadCap Software, Inc. (http://www.madcapsoftware.com), the leader in multi-channel content authoring and a showcase company for Microsoft (NASDAQ: MSFT) Visual Studio and Microsoft XPS, today announced the launch of MadCap Flare 8.0. Flare is the industry's leading technical authoring application for publishing online Help, knowledge bases, policy and procedure manuals, user manuals, and other forms of content. Only MadCap Flare lets authors create a single project and then directly publish it in multiple formats optimized for the Web, mobile devices, desktops, and print ...
2012-03-01
HOUSTON - A drug that relieves the severe symptoms of a life-threatening bone marrow cancer called myelofibrosis also improves the survival of patients with the disease, according to a phase III clinical trial published in the March 1 edition of New England Journal of Medicine.
"The Phase I/II clinical trial showed that ruxolitinib improves quality of life for many patients with myelofibrosis and now this phase III study indicates that the drug extends survival in a patient population that has lacked effective treatments," said study principal investigator Srdan Verstovsek, ...
2012-03-01
STANFORD, Calif. — People with a blood cancer — myelofibrosis — can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the Stanford University School of Medicine. The results of the multi-site phase-3 trial, which will be published in the March 1 issue of the New England Journal of Medicine, led the Food and Drug Administration to approve the drug in November as treatment for people with intermediate or advanced cases of the disease.
Ruxolitinib is marketed as Jakafi ...
LAST 30 PRESS RELEASES:
[Press-News.org] American Heart Association comment: FDA announces safety changes on labeling for some statins
